{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06041568",
            "orgStudyIdInfo": {
                "id": "IGM-2323-101"
            },
            "organization": {
                "fullName": "IGM Biosciences, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study on Imvotamab in Severe Lupus",
            "officialTitle": "A Early-phase, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Drug Level Monitoring, and Drug Effects of Imvotamab in Participants With Severe Lupus Who Have Failed Standard Therapies",
            "therapeuticArea": [
                "Immunology and Rheumatology"
            ],
            "study": "study-on-imvotamab-in-severe-lupus"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-11",
            "studyFirstSubmitQcDate": "2023-09-11",
            "studyFirstPostDateStruct": {
                "date": "2023-09-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "IGM Biosciences, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine the safety and tolerability of imvotamab in patients with severe systemic lupus erythematosus who have failed prior therapies.\n\nParticipants will be given imvotamab through a vein (i.e., intravenously).",
            "detailedDescription": "This is a Phase 1b, randomized, placebo-controlled, multicenter study to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of imvotamab in adult patients with systemic lupus erythematosus (SLE). Approximately 18 patients will be assigned to different sequentially dose escalation cohorts."
        },
        "conditionsModule": {
            "conditions": [
                "Systemic Lupus Erythematosus",
                "Lupus Erythematosus"
            ],
            "keywords": [
                "Lupus",
                "SLE",
                "Severe Lupus",
                "Severe systemic lupus erythematosus",
                "Systemic lupus erythematosus"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 18,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Imvotamab (Dose Escalation)",
                    "type": "EXPERIMENTAL",
                    "description": "Imvotamab administered intravenously",
                    "interventionNames": [
                        "Drug: Imvotamab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Imvotamab",
                    "description": "Administered intravenously",
                    "armGroupLabels": [
                        "Imvotamab (Dose Escalation)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Safety and tolerability of imvotamab",
                    "description": "Incidence of adverse events (AEs), serious adverse events (SAEs), including serious infectious events and opportunistic infections",
                    "timeFrame": "Up to Week 52"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Age \u2265 18 years at the time of signing ICF\n* Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (ACR) Classification Criteria at least 16 weeks or more prior to screening\n* Highly active SLE disease, as demonstrated by a total systemic lupus erythematosus disease activity index (SLEDAI-2K) total score of \u2265 10 at screening\n* Active SLE disease despite treatment with at least 1 immunosuppressive or biologic standard-of-care agent (e.g., methotrexate, azathioprine, mycophenolate mofetil, belimumab, anifrolumab) determined at the discretion of the investigator after at least 3 months of treatment.\n* It must be planned that the background standard-of-care treatment remains at a stable dose throughout the Screening Period and up to Week 8.\n\nKey Exclusion Criteria:\n\n* Pregnant or breastfeeding or intending to become pregnant during the study or within 3 months after the final dose of imvotamab.\n* Any lupus-associated neuropsychiatric disease.\n* Active lupus nephritis with estimated glomerular filtration rate (eGFR) \\< 30 mL/min/1.73 m2, calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation, classified as World Health Organization (WHO) Class IV.\n* Prednisone-equivalent \\> 30 mg/day, including immediate and extended-release oral formulations.\n* Drug-induced lupus.\n* Participants with a history of catastrophic or severe anti-phospholipid syndrome within 12 months prior to screening.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials",
                    "role": "CONTACT",
                    "phone": "(877) 544-6728",
                    "email": "IGM-2323-101@igmbio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Rebecca Kunder",
                    "affiliation": "IGM Biosciences",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "TriWest Research Associates",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92108",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials",
                            "role": "CONTACT",
                            "email": "IGM-2323-101@igmbio.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "East Bay Rheumatology",
                    "status": "RECRUITING",
                    "city": "San Leandro",
                    "state": "California",
                    "zip": "94578",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials",
                            "role": "CONTACT",
                            "email": "IGM-2323-101@igmbio.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.72493,
                        "lon": -122.15608
                    }
                },
                {
                    "facility": "Omega Research, DeBary",
                    "status": "RECRUITING",
                    "city": "DeBary",
                    "state": "Florida",
                    "zip": "32713",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials",
                            "role": "CONTACT",
                            "email": "IGM-2323-101@igmbio.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.88305,
                        "lon": -81.30868
                    }
                },
                {
                    "facility": "Integral Rheumatology & Immunology Specialists",
                    "status": "RECRUITING",
                    "city": "Plantation",
                    "state": "Florida",
                    "zip": "33324",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials",
                            "role": "CONTACT",
                            "email": "IGM-2323-101@igmbio.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.13421,
                        "lon": -80.23184
                    }
                },
                {
                    "facility": "Stryde Research",
                    "status": "RECRUITING",
                    "city": "Allen",
                    "state": "Texas",
                    "zip": "75013",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials",
                            "role": "CONTACT",
                            "email": "IGM-2323-101@igmbio.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.10317,
                        "lon": -96.67055
                    }
                },
                {
                    "facility": "Precision Comprehensive Clinical Research",
                    "status": "RECRUITING",
                    "city": "Grapevine",
                    "state": "Texas",
                    "zip": "76051",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials",
                            "role": "CONTACT",
                            "email": "IGM-2323-101@igmbio.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.93429,
                        "lon": -97.07807
                    }
                },
                {
                    "facility": "Prolato Clinical Research Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77054",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials",
                            "role": "CONTACT",
                            "email": "IGM-2323-101@igmbio.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Care and Cure Clinic",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77090",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials",
                            "role": "CONTACT",
                            "email": "IGM-2323-101@igmbio.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Seoul National University Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "country": "Korea, Republic of",
                    "contacts": [
                        {
                            "name": "Clinical Trials",
                            "role": "CONTACT",
                            "email": "IGM-2323-101@igmbio.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Niepubliczny Zak\u0142ad Opieki Zdrowotnej Lecznica MAK-MED w Nadarzynie",
                    "status": "RECRUITING",
                    "city": "Nadarzyn",
                    "country": "Poland",
                    "contacts": [
                        {
                            "name": "Clinical Trials",
                            "role": "CONTACT",
                            "email": "IGM-2323-101@igmbio.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.09438,
                        "lon": 20.80776
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008180",
                    "term": "Lupus Erythematosus, Systemic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003240",
                    "term": "Connective Tissue Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11177",
                    "name": "Lupus Erythematosus, Systemic",
                    "asFound": "Systemic Lupus Erythematosus",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6464",
                    "name": "Connective Tissue Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}